Cancer Supportive Care Market By Cancer (Lung Cancer, Liver Cancer, Breast Cancer, Leukemia, Prostate Cancer, Ovarian Cancer, Bladder Cancer), By Sales Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), By Therapeutic Area (Oral Mucositis And Dry Mouth, Chemotherapy Induced Nausea And Vomiting Cancer Pain, Chemotherapy Induced Anemia, Chemotherapy Induced Neutropenia, Bone Metastases) - Growth, Future Prospects And Competitive Analysis, 2016 - 2024

Supportive care is a high-priority area in cancer care and management. Prevention of radiotherapy and chemotherapy-induced anemia, management of mucosal injury, treatment of dyspnea, management of cancer pain, venous thromboembolism, bone metastases, cardiovascular toxicity, and others hold critical significance, and specific guidelines have been established for delivering the best cancer treatment outcomes.

This report, titled "Cancer Supportive Care Market: Growth, Future Prospects, and Competitive Analysis, 2016–2024," is intended to offer industry investors, company executives, and other industry participants with in-depth insights to enable them to make informed strategic decisions related to the opportunities in the cancer supportive care drugs market. The major target audience of this study includes industry investors, cancer drug manufacturers, distributors, and institutional scholars.

This study classifies the global cancer supportive care market into types of therapeutics, cancer types, sales channels, and geographical distribution. Based on therapeutic types, the overall market is studied for Oral Mucositis and Dry Mouth, Chemotherapy-Induced Nausea and Vomiting, Cancer Pain, Chemotherapy-Induced Anemia, Chemotherapy-Induced Neutropenia, and Bone Metastases. Lung cancer, liver cancer, breast cancer, leukemia, prostate cancer, ovarian cancer, bladder cancer, and other cancers are the major oncology areas for which the cancer supportive care market is studied.

The sales channels considered for the distribution of cancer-supportive care drugs are hospital pharmacies, retail pharmacies, and compounding pharmacies. Market size and forecasts for each mentioned segment are provided in this report for the period 2013–2024 (US$ Mn), along with respective CAGRs (value %) for the period 2016–20244.

Geographically, the global market for supportive cancer care is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East and Africa

The market size and respective forecasts for these regional and country-level markets are presented in this study for the period 2013–2024. Market growth rates for the forecast period 2016–2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global cancer supportive care market.

Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global cancer supportive care market's competitive landscape. This report concludes with a company profiles section that highlights major information about the key players engaged in the development, manufacture, and sale of cancer-supportive care drugs.

Based on the types of cancers for which supportive care is significantly in demand, the global cancer supportive care market is segmented as follows:

  • Lung Cancer
  • Liver Cancer
  • Breast Cancer
  • Leukemia
  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Others

Lung cancer is estimated to be the largest segment among the cancer types considered, with the highest demand for cancer-supportive care. The primary indicator of the segment's dominance is the high incidence of lung cancer caused by environmental and lifestyle factors. Significant growth in the incidence of lung cancer in the Middle East, Africa, and Asia Pacific will further facilitate the high demand for lung cancer treatment and supportive care in the regions. In addition, the incidence of breast and prostate cancer is notably high worldwide. While the concurrent rise in survival rates indicates impressive success in treatment outcomes and, as a result, supportive care for such cancers, 

Based on the type of sales channel, the global cancer supportive care market is segmented as follows:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Compounding pharmacies

Among the considered sales channels, hospitals and clinics capture the largest revenue share in the global cancer-supportive care market. However, the geographic distribution of these sales channels varies considerably in revenue share in the global cancer-supportive care market. However, the geographic distribution of these sales channels varies considerably. This mix majorly varies across countries due to the prevalent healthcare practices, types of formulations used, and reimbursement.

The distribution of oncology drugs through hospital pharmacies is highest in European countries such as the U.K., Spain, and Italy. Oncology drugs are primarily distributed through retail pharmacies in North America and France. The shift toward oral medicines as opposed to injections in targeted therapies has contributed greatly to the rapid upswing of retail pharmacies in the cancer-supportive care market.

Based on the therapeutic areas, the global market for supportive cancer care is segmented as follows:

  • Oral mucositis and dry mouth
  • Chemotherapy-induced nausea and vomiting
  • Cancer Pain
  • Chemotherapy-induced anemia
  • Chemotherapy-Induced Neutropenia
  • Bone Metastases

Supportive care interventions can assist in preventing or minimizing the adverse effects of cancer treatments across all phases of cancer management. Though associated pain is the largest addressable area in supportive care regimens, chemotherapy-induced anemia and chemotherapy-induced neutropenia together claim the largest market segment in the overall cancer supportive care market. Drugs such as erythropoietin-stimulating agents are largely used for hematological management during cancer treatments. Other therapeutic areas, such as chemotherapy-induced nausea and vomiting, also attract significant focus, with several innovative CINV drugs being rapidly adopted across geographies.

The world's aging population is rapidly increasing the number of geriatric cancer patients. For this group of patients, supportive care is critically important to augment survival and clinical outcomes. Providers of supportive care products are engaged in a severe race to maintain their share and stronghold in the market, particularly with the steady advancement of life-extending cancer medications. However, such treatment drugs are found to be prohibitively expensive, particularly in developing economies where reimbursement coverage lags behind that of Western Europe and North America. This phenomenon will support the mainstay and continued steady progress of the market for cancer-supportive drugs in developing Asian, Middle Eastern, and African countries.

For the purpose of this study, the global market for supportive cancer care is categorized as follows:

  • North America (U.S., Canada)
  • Europe (U.K., Germany, rest of Europe)
  • Asia Pacific (Japan, China, Australia, and the Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Saudi Arabia, South Africa, and the rest of the Middle East and Africa

North America and Europe are the two largest markets for cancer-supportive care drugs. The huge population base and corresponding patient pool are the chief contributors to the dominance of Asia Pacific on the global front. It is anticipated that North America and Western Europe will witness moderate yet steady growth through the forecast period. The fastest market growth will be observed in the Asia Pacific on the grounds of a significant population and corresponding patient pool, the rising prevalence of cancer in the region, and the swift development of healthcare infrastructure.

Government initiatives, the growing commercialization of new supportive care drugs, and the rising adoption of direct-to-consumer marketing are predicted to be the key trends in the developed markets. Further clarity in reimbursement policies will open new opportunities for drug manufacturers in this market.

Frequently Asked Questions:

The market for Cancer Supportive Care Market is expected to reach US$ 34,214.7 Mn By 2024.

The Cancer Supportive Care Market is expected to see significant CAGR growth over the coming years, at 4.4%.

The report is forecasted from 2016-2024.

The base year of this report is 2015.

Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Dec 2016
Category:  Pharmaceuticals
Report ID:   58293
Report Format:   PDF
Pages:   120
Rating:    4.3 (55)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support